内镜黏膜下剥离术治疗北美大型队列浅表性胃肿瘤的疗效
该研究分析2010至2019年北美25中心347例胃内镜黏膜下剥离术(ESD)患者,整块切除率92%、R0切除率82%,早期胃癌分别为94%和75%。术中穿孔6.6%(82%内镜治疗成功),迟发出血2.6%,无迟发穿孔或操作相关死亡,局部复发3.9%且均见于非治愈性切除后。
要点
- 胃ESD整块切除率92%、R0切除率82%,早期胃癌为94%和75%。
- 术中穿孔6.6%,其中82%经内镜治疗成功;迟发出血2.6%。
- 局部复发3.9%,均发生于非治愈性切除后;异时病灶6.9%。
核心结论
- ESD是浅表性胃肿瘤的高效治疗方式,应被视为北美患者的可行选择。
- 局部复发风险低,且仅发生于非治愈性切除后。
- 需要仔细的内镜监测以发现和治疗异时病灶。
研究设计与样本
- 分析2010年至2019年北美25个中心347例接受胃ESD患者的数据。
- 收集人口学、病灶特征、操作细节、不良事件、治疗结局、局部复发及末次随访生存状态。
- 277例有随访数据者,初次ESD至末次临床或内镜评估的中位间隔为364天。
主要发现
- 90例(26%)为低级别腺瘤或异型增生,82例(24%)为高级别异型增生,139例(40%)为早期胃癌,36例(10%)为神经内分泌肿瘤。
- 全部病灶整块切除率92%、R0切除率82%;早期胃癌94%和75%;腺瘤及低级别异型增生93%和92%;高级别异型增生89%和87%;神经内分泌肿瘤92%和75%。
- 术中穿孔6.6%,其中82%经内镜治疗成功;迟发出血2.6%;无迟发穿孔或操作相关死亡。
- 局部复发3.9%,均发生于非治愈性ESD切除后;异时病灶14例(6.9%)。
- 277例临床随访者中1例死于异时性胃癌,发生于初次ESD后2.5年。
临床怎么用
- 作者认为ESD是浅表性胃肿瘤的高效治疗方式,应被视为北美患者的可行选择。
- 作者指出局部复发风险低且仅见于非治愈性切除后,需要仔细内镜监测以发现和治疗异时病灶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Endoscopic submucosal dissection (ESD) is a widely accepted treatment option for superficial gastric neoplasia in Asia, but there are few data on outcomes of gastric ESD from North America. We aimed to evaluate the safety and efficacy of gastric ESD in North America. METHODS: We analyzed data from 347 patients who underwent gastric ESD at 25 centers, from 2010 through 2019. We collected data on patient demographics, lesion characteristics, procedure details and related adverse events, treatment outcomes, local recurrence, and vital status at the last follow up. For the 277 patients with available follow-up data, the median interval between initial ESD and last clinical or endoscopic evaluation was 364 days. The primary endpoint was the rate of en bloc and R0 resection. Secondary outcomes included curative resection, rates of adverse events and recurrence, and gastric cancer-related death. RESULTS: Ninety patients (26%) had low-grade adenomas or dysplasia, 82 patients (24%) had high-grade dysplasia, 139 patients (40%) had early gastric cancer, and 36 patients (10%) had neuroendocrine tumors. Proportions of en bloc and R0 resection for all lesions were 92%/82%, for early gastric cancers were 94%/75%, for adenomas and low-grade dysplasia were 93%/ 92%, for high-grade dysplasia were 89%/ 87%, and for neuroendocrine tumors were 92%/75%. Intraprocedural perforation occurred in 6.6% of patients; 82% of these were treated successfully with endoscopic therapy. Delayed bleeding occurred in 2.6% of patients. No delayed perforation or procedure-related deaths were observed. There were local recurrences in 3.9% of cases; all occurred after non-curative ESD resection. Metachronous lesions were identified in 14 patients (6.9%). One of 277 patients with clinical follow up died of metachronous gastric cancer that occurred 2.5 years after the initial ESD. CONCLUSIONS: ESD is a highly effective treatment for superficial gastric neoplasia and should be considered as a viable option for patients in North America. The risk of local recurrence is low and occurs exclusively after non-curative resection. Careful endoscopic surveillance is necessary to identify and treat metachronous lesions.
引用
- Ngamruengphong S, Ferri L, Aihara H, et al. Efficacy of Endoscopic Submucosal Dissection for Superficial Gastric Neoplasia in a Large Cohort in North America. Clin Gastroenterol Hepatol. 2020. PMID: 32565290. doi:10.1016/j.cgh.2020.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。